Mild cognitive impairment (MCI) is considered a transitional stage between normal aging and dementia, in par ticular Alzheimer's disease (AD) [1] . Th e rate of conversion from MCI to AD is approximately 15% per year [2] .
Identifying prodromal AD with [ 11 C]PIB PET
Koivunen and colleagues [7] performed amyloid imaging with [
11 C]PIB PET at baseline and after 2 years of followup in a sample of 29 MCI patients. Th ey divided MCI patients into converters and non-converters, based on clinical diagnosis at follow-up. At baseline, MCI converters had substantially higher mean [ 11 C]PIB levels com pared to MCI non-converters in the posterior cingulate, lateral frontal and temporal cortices and in putamen and caudate nucleus. After classifying [ 11 C]PIB PET scans into either positive or negative, using a cut-off point of 1.5 standardized uptake value ratio (SUVr), 21 of 29 (72%) subjects with MCI had a positive [ 11 C]PIB-negative MCI patients did so. Th ese results are in accordance with several previous studies [8, 9] and indicate that [ 11 C]PIB PET predicts progression to AD in MCI patients.
Abstract
Patients with mild cognitive impairment are at an increased risk of progression to Alzheimer's disease. However, not all patients with mild cognitive impairment progress, and it is diffi cult to accurately identify those patients who are in the prodromal stage of Alzheimer's disease. In a recent paper, Koivunen and colleagues report that Pittsburgh compound-B, an amyloid-beta positron emission tomography ligand, predicts the progression of patients with mild cognitive impairment to Alzheimer's disease. Of 29 subjects with mild cognitive impairment, 21 (72%) had a positive Pittsburgh compound-B positron emission tomography baseline scan. In their study, 15 of these 21 (71%) patients progressed to Alzheimer's disease, whilst only 1 out of 8 (12.5%) Pittsburgh compound-B-negative patients with mild cognitive impairment did so. Moreover, in these mild cognitive impairment patients, the overall amyloid burden increased approximately 2.5% during the follow-up period. This is consistent with other longitudinal amyloid imaging studies that found a similar increase in amyloid deposition over time in patients with mild cognitive impairment. These studies together challenge current theories that propose a fl attening of the increase of brain amyloid deposition already in the preclinical stage of Alzheimer's disease. These fi ndings may have important implications for the design of future clinical trials aimed at preventing progression to Alzheimer's disease by lowering the brain amyloid-beta burden in patients with mild cognitive impairment.
Temporal changes in amyloid burden in MCI
Recently, Jack and colleagues [10] proposed a hypothetical model that positioned established and novel biomarkers in the continuum of AD. Th is model elaborates on the amyloid-cascade hypothesis [11] , which states that accumulation of Aβ initiates a cascade of neuropathological events, such as the formation of neurofi brillary tangles and neuroinfl ammation. Th is may in turn lead to neurodegeneration that presumably is followed by cognitive deterioration and fi nally results in dementia. Accumulation of Aβ is thought to set in decades before the fi rst cognitive complaints arise, starts to accelerate already in the preclinical stage of AD, and reaches a relative plateau at the time symptoms emerge [12] .
In the study by Koivunen and colleagues, the overall amyloid burden in MCI patients increased approximately 2.5% in 2 years. Th is increase was most prominent for those patients who did not convert to AD. However, the overall increase in amyloid deposition was only modest, whilst hippocampal volumes decreased more strongly. Th is is in line with the idea that Aβ starts off the cascade and may uncouple at a later time point from neurodegenerative processes. Previous studies that related the presence of amyloid plaques with the course of brain atrophy [13] and glucose hypometabolism [14] also found this dissociation between amyloid deposition and structural and functional changes. Th e fi ndings of Koivunen and colleagues suggest that the time span between deposition of amyloid and actual neurodegeneration may perhaps be shorter than previously assumed, given the dynamic Aβ changes in MCI patients in this study.
Th e fi nding of increased amyloid burden over time in MCI patients is consistent with other recent longitudinal amyloid imaging studies. Villemagne and colleagues [15] reported that 65 MCI patients had a mean increase in [ 11 C]PIB retention of 2.1% over a 20-month follow-up period (annual increase of 1.3%). A study by Jack and colleagues [16] showed an annual increase of 1.7% in 32 MCI patients. Moreover, in an unpublished study from our group in 12 MCI patients, [ 11 C]PIB binding increased by 5.0% over a 30-month period (annual increase 2%). Th ese results are in accordance with the 2.5% increase over 24 months (annual increase 1.25%) reported by Koivunen and colleagues. In all these longitudinal studies, the increased amyloid burden was primarily driven by MCI patients that displayed high [ 11 C]PIB retention at baseline. Taken together, amyloid deposition seems to increase in both MCI converters and nonconverters, thereby challenging the theory that amyloid plaque load is stable in the prodromal stage of AD.
A limitation of the study by Koivunen and colleagues, especially given its longitudinal design, is the use of SUVr, which overestimates [ 11 C]PIB binding in compari son with fully quantitative kinetic models [17] . Further more, SUVr does not correct for factors that are inherently associated with disease progression, such as hetero geneous fl ow eff ects in the region of interest compared to the reference region. We therefore argue that quantitative modeling, and thus dynamic PET scanning, is essential for longitudinal amyloid imaging studies.
Amyloid imaging in clinical trials
Th e fi nding that [ 11 C]PIB PET can help identify prodromal AD patients and that most MCI patients show an increased amyloid burden over time may have implications for the design of future clinical trials. First of all, amyloid imaging may be used as an enrichment strategy by enabling the selection of subjects at risk for AD, in order to administer disease-modifying agents to the right patients. Secondly, Aβ PET ligands may be used as a secondary outcome measure to provide biological insight into cognitive primary outcome measures. Finally, amyloid imaging can be applied as a surrogate outcome measure to test whether anti-amyloid therapies are effi cacious by measuring the amount of fi brillary Aβ prior to and after the time window of the intervention. In this respect one should note that patients with prodromal AD may still show an increase in amyloid plaque formation, instead of the previously assumed plateau due to an equilibrium between production and clearance of Aβ. Th is will aff ect power calculations for such trials. Current development of several fl uor-18-labeled amyloid PET tracers (which have a longer half-life time compared to carbon-11) will further increase the availability and applicability of amyloid imaging in both clinical practice and for scientifi c purposes.
Conclusion
Koivunen and colleagues showed that amyloid imaging may be used to predict clinical progression to AD in patients with MCI and that, contrary to current hypothetical biomarker models, amyloid deposition increases over time in patients with MCI. Th ese fi ndings are relevant for the design of future clinical trials aimed at the prevention of progression to AD by lowering the Aβ burden in the brains of patients with MCI. C labeled Pittsburgh compound-B; Aβ, amyloid-beta; AD, Alzheimer's disease; MCI, mild cognitive impairment; PET, positron emission tomography; SUVr, standardized uptake value ratio.
